Evidence map›Paper›PMID 37558863›Full record

ArticleCurrent medical science2023

Advancement and Applications of Nanotherapy for Cancer Immune Microenvironment.

Jun-Ju He, Qing-Qing Li, Chen Zhao, Jin Zhou, Jie Wu, Hui-Bo Zhang, Ya-Qi Zhao, Hao-Han Zhang, Tian-Yu Lei, Xin-Yi Zhao and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Current medical science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Jun-Ju He *Cancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Qing-Qing Li *Cancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Chen ZhaoCancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Jin ZhouCancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Jie WuCancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Hui-Bo ZhangCancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Ya-Qi ZhaoCancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Hao-Han ZhangCancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Tian-Yu LeiCancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Xin-Yi ZhaoCancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Zuo YouDepartment of Traditional Chinese Medicine, Xianfeng County People's Hospital, Enshi, 445000, China.
Qi-Bin SongCancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China.
Bin XuCancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China. xubin_oncology@whu.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer treatment has evolved rapidly due to major advances in tumor immunity research. However, due to the complexity, heterogeneity, and immunosuppressive microenvironment of tumors, the overall efficacy of immunotherapy is only 20%. In recent years, nanoparticles have attracted more attention in the field of cancer immunotherapy because of their remarkable advantages in biocompatibility, precise targeting, and controlled drug delivery. However, the clinical application of nanomedicine also faces many problems concerning biological safety, and the synergistic mechanism of nano-drugs with immunity remains to be elucidated. Our study summarizes the functional characteristics and regulatory mechanisms of nanoparticles in the cancer immune microenvironment and how nanoparticles activate and long-term stimulate innate immunity and adaptive immunity. Finally, the current problems and future development trends regarding the application of nanoparticles are fully discussed and prospected to promote the transformation and application of nanomedicine used in cancer treatment.

Indexed as

NeoplasmsAdaptive ImmunityDrug Delivery SystemsHumansImmunotherapyNanomedicineTumor Microenvironmentimmunotherapynanotherapytumor microenvironment

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.